Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Poolbeg Pharma Launches £4.1 Million Fundraise to Advance Cancer and Obesity Treatments

Poolbeg Pharma PLC (LSE:POLB)has announced plans to raise approximately £4.1 million through a combination of share placing and subscriptions, aiming to accelerate the development of two of its key experimental drug programmes. The funding is expected to support upcoming clinical trials focused on cancer …

Team Kalkine | 20 May 2025

Arecor (AIM: AREC) and Skye Bioscience Collaborate on Enhanced Formulation of Obesity Drug Candidate

Arecor Therapeutics plc (AIM: AREC)has announced a new collaboration with US-based Skye Bioscience (Nasdaq: SKYE) to develop a higher concentration formulation of nimacimab, a monoclonal antibody currently under investigation for the treatment of obesity and related metabolic conditions.

Team Kalkine | 19 May 2025

Genflow Biosciences Advances SIRT6 Gene Therapy Patent in Japan

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has announced progress in securing intellectual property protection for its core gene therapy technology in Japan, with the country’s patent office advancing a key application to the national examination stage.

Team Kalkine | 15 May 2025

GSK Acquires Promising Liver Disease Drug Efimosfermin in $2 Billion Deal to Tackle Global Hepatology Crisis

In a strategic move to bolster its liver disease portfolio, GSK plc (LSE:GSK) has announced the acquisition of efimosfermin alfa, a promising investigational treatment for steatotic liver disease (SLD), from Boston Pharmaceuticals. The deal, valued at $2 billion, includes an upfront payment of $1.2 …

Team Kalkine | 14 May 2025

GSK Delivers Positive Start to 2025 with Surge in Specialty Medicines and Robust Pipeline Momentum

GSK (LSE:GSK)has made a positive start to 2025, posting growth in sales, profits, and earnings, with performance underpinned by its thriving Specialty Medicines segment and strategic investments in pipeline advancement.

Team Kalkine | 30 April 2025

Smith+Nephew Delivers Q1 Revenue Growth, Maintains 2025 Outlook Amid Global Headwinds

Smith+Nephew plc (LSE:SN, NYSE:SNN)reported growth for the first quarter ended 29 March 2025, driven by operational improvements and new product launches, despite external challenges including continued headwinds from China and one fewer trading day compared to the prior year.

Team Kalkine | 30 April 2025

AstraZeneca Shares Dip Despite Increase in Earnings and Oncology Surge

Shares in AstraZeneca PLC (LSE:AZN) dropped by 4% in early London trading following the release of its first-quarter 2025 results, as a slight miss on revenue forecasts overshadowed stronger-than-expected earnings and a standout performance in its oncology segment.

Team Kalkine | 29 April 2025

Reckitt Benckiser Posts Q1 2025 Results, Driven by Emerging Markets and Powerbrands

Reckitt Benckiser Group PLC reported a resilient performance in the first quarter of 2025, with like-for-like (LFL) net revenue for Core Reckitt increasing by 3.1%. This growth was primarily fuelled by a performance from its Powerbrands, notably Germ Protection (up 7.5%) and Intimate Wellness …

Team Kalkine | 23 April 2025

GSK plc (LSE/NYSE: GSK) Receives CDC Recommendation for Penmenvy in Adolescent Meningococcal Vaccination

GSK plc (LSE/NYSE: GSK) has received a significant step forward in the U.S. vaccination landscape, as the CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of Penmenvy, a combined meningococcal vaccine. Penmenvy, which protects against meningococcal groups A, B, C, …

Team Kalkine | 17 April 2025

Assura Agrees to £1.6 Billion Cash Acquisition by Sana Bidco

Assura plc (LSE:AGR), a prominent healthcare infrastructure investor and developer in the UK and Ireland, has agreed to a recommended cash acquisition by Sana Bidco Limited, in a deal that values the company at approximately £1.61 billion on a fully diluted basis.

Team Kalkine | 09 April 2025
Support

Hi! How can we help you today?

Loading…